Autolus Therapeutics (AUTL) Hits New 1-Year High at $40.98

Autolus Therapeutics Ltd – (NASDAQ:AUTL)’s share price hit a new 52-week high on Thursday . The company traded as high as $40.98 and last traded at $38.89, with a volume of 50475 shares changing hands. The stock had previously closed at $31.20.

A number of brokerages have recently weighed in on AUTL. Goldman Sachs Group began coverage on Autolus Therapeutics in a report on Thursday, July 26th. They issued a “neutral” rating on the stock. HC Wainwright began coverage on Autolus Therapeutics in a report on Wednesday, October 24th. They issued a “buy” rating on the stock. Wells Fargo & Co began coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 target price on the stock. William Blair began coverage on Autolus Therapeutics in a research note on Tuesday, July 17th. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group began coverage on Autolus Therapeutics in a research note on Tuesday, July 17th. They issued a “buy” rating and a $37.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $40.00.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at approximately $132,000. TD Asset Management Inc. bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at approximately $258,000. ING Groep NV bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at approximately $402,000. Bank of Montreal Can bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at approximately $429,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at approximately $498,000. 21.17% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2018/11/10/autolus-therapeutics-autl-hits-new-1-year-high-at-40-98.html.

Autolus Therapeutics Company Profile (NASDAQ:AUTL)

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Featured Article: The risks of owning bonds

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit